News

A recent study reported that relapse prevention was the most influential factor in treatment selection, with respondents favoring profiles similar to ravulizumab over other approved options for NMOSD.

MOGAD Awareness Month highlights the evolution of myelin oligodendrocyte glycoprotein antibody–associated disease from a once-misclassified condition to a distinct neuroimmunologic disorder.

A data-driven slideshow for National Public Health Week highlights the global burden of neurologic diseases, featuring key statistics on prevalence, disability, and workforce gaps across major conditions.

Alexander Shustorovich, DO, an interventional pain medicine physician, discussed a unique case of sustained pain relief after spinal cord stimulation trial and its implications for neuromodulation strategies.

Here's some of what is coming soon to NeurologyLive® this week.

Real-world MOGAD data show tocilizumab drives relapse-free control, improves disability and vision, but requires infection monitoring.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is AAN Annual Meeting History!

Diana Castro, MD, founder and director of the Neurology and Neuromuscular Care Center, discussed early phase 1b data on salanersen, an investigational therapy for patients living with spinal muscular atrophy.

Neurology News Network for the week ending April 11, 2026. [WATCH TIME: 4 minutes]

A multicenter study showed that kappa free light chain index offers strong diagnostic accuracy for distinguishing MS from MOGAD and NMOSD, with added value when combined with oligoclonal band testing in complex cases.

Frontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you a 2-part exclusive interview with Brian Edlow, MD, of Mass General Brigham. [LISTEN TIME: 26 minutes]

Frontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you a 2-part exclusive interview with Brian Edlow, MD, of Mass General Brigham. [LISTEN TIME: 26 minutes]

Lead Investigators explain blood-based “Clock Model” that uses plasma p-tau217 levels to estimate when symptoms of Alzheimer disease may begin, with an average prediction error of approximately 3 to 4 years.

FDA accepts Ultragenyx’s UX111 gene therapy BLA for Sanfilippo A, setting a September 2026 decision date.

The director of neuromuscular medicine at Marcus Neuroscience Institute shared findings from an analysis presented at MDA 2026 that compared real-world infection rates associated with generalized myasthenia gravis therapies. [WATCH TIME: 8 minutes]

In recognition of National Public Health Week, held April 6-12, NeurologyLive summarizes recent literature showing that environmental exposures are associated with increased risk of neurologic disorders.

A meta-analysis of randomized trials confirmed modafinil improves both objective and subjective measures of daytime sleepiness in narcolepsy.

High-dose influenza vaccination was associated with a lower risk of incident Alzheimer dementia compared with standard-dose vaccination among adults aged 65 years and older in a large US claims-based cohort study.

The director of the Neurology Residency Program at the Marcus Neuroscience Institute talked about the role of research, patient empowerment, and expanding treatment options in multiple sclerosis. [WATCH TIME: 5 minutes]

A small case series published in JAMA Neurology found interstitial lung disease in 9% of long-term ocrelizumab-treated patients, with cases emerging after a mean of 10.5 years of therapy.

A neuroimmunology fellow at the Cleveland Clinic shared her experience attending the 2026 ACTRIMS Forum, specifically focusing on the late-breaking data presented in multiple sclerosis.

The director of the Neurology Residency Program at the Marcus Neuroscience Institute discussed the importance of early recognition of invisible symptoms in comprehensive multiple sclerosis care. [WATCH TIME: 9 minutes]

Stay informed on the latest therapeutic advancements with this clinical recap from the NeurologyLive® team, featuring a centralized look at 7 FDA-approved treatments from the first quarter of 2026.

Alkermes has initiated the phase 3 Brilliance program for alixorexton in narcolepsy, building on prior phase 1 and 2 data showing significant improvements in wakefulness and daytime sleepiness.

Steven Markos, MD, a physician at Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed a two-week inpatient rehabilitation program and its impact on functional and speech outcomes in Parkinson disease.

A new post hoc analysis of the CHAMPION-NMOSD trial reported similar safety and relapse prevention outcomes with ravulizumab-cwvz in patients with and without prior rituximab exposure.

Findings from a recently published study suggest peripapillary retinal nerve fiber layer thickness measured by OCT could support clinicians with early distinction between MOGAD-optic neuritis and NMOSD-optic neuritis.

Experts discuss key takeaways in the latest ischemic stroke guidelines, including the transition toward tenecteplase, advances in multimodal imaging, and growing attention to pediatric stroke care. [WATCH TIME: 3 minutes]